GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NeoImmuneTech Inc (XKRX:950220) » Definitions » Deferred Policy Acquisition Costs

NeoImmuneTech (XKRX:950220) Deferred Policy Acquisition Costs


View and export this data going back to 2021. Start your Free Trial

What is NeoImmuneTech Deferred Policy Acquisition Costs?

Deferred Policy Acquisition Costs only applies to banks and insurance companies.


NeoImmuneTech (XKRX:950220) Business Description

Industry
Traded in Other Exchanges
N/A
Address
2400 Research Boulevard, Suite 250, Rockville, MD, USA, 20850
NeoImmuneTech Inc is a clinical-stage T cell-focused biotech company dedicated to the discovery and development of novel immuno-therapeutics. Its lead asset NT-I7 is the clinical stage IL-7, which enhances the body's immune function to address key resistance mechanisms in Immuno-Oncology and deadly infectious diseases.